Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Expenses: 2010-2025

Historic Operating Expenses for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $30.4 million.

  • Heron Therapeutics' Operating Expenses rose 9.28% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.0 million, marking a year-over-year decrease of 9.82%. This contributed to the annual value of $117.2 million for FY2024, which is 32.10% down from last year.
  • Latest data reveals that Heron Therapeutics reported Operating Expenses of $30.4 million as of Q3 2025, which was up 4.87% from $29.0 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Operating Expenses peaked at $86.4 million during Q1 2022, and registered a low of $26.4 million during Q4 2024.
  • Moreover, its 3-year median value for Operating Expenses was $31.0 million (2024), whereas its average is $34.2 million.
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Operating Expenses was 19.75% (2022), while the steepest drop was 49.11% (2022).
  • Quarterly analysis of 5 years shows Heron Therapeutics' Operating Expenses stood at $74.2 million in 2021, then crashed by 49.11% to $37.8 million in 2022, then dropped by 8.44% to $34.6 million in 2023, then declined by 23.69% to $26.4 million in 2024, then rose by 9.28% to $30.4 million in 2025.
  • Its Operating Expenses stands at $30.4 million for Q3 2025, versus $29.0 million for Q2 2025 and $27.3 million for Q1 2025.